Edition:
United States

Veloxis Pharmaceuticals A/S (VELOX.CO)

VELOX.CO on Copenhagen Stock Exchange

1.00DKK
11:11am EDT
Change (% chg)

kr.0.05 (+5.85%)
Prev Close
kr.0.94
Open
kr.0.94
Day's High
kr.1.01
Day's Low
kr.0.93
Volume
1,942,008
Avg. Vol
1,126,409
52-wk High
kr.1.38
52-wk Low
kr.0.92

Select another date:

Tue, Sep 12 2017

BRIEF-Veloxis increases share capital in connection with exercise of warrants

* Veloxis increases share capital in connection with exercise of warrants

BRIEF-Veloxis Pharmaceuticals H1 revenue $16.17 million

* Veloxis pharmaceuticals a/s says revenue reached $16.17 million in first half of 2017 representing an increase of 394% compared to same period last year

BRIEF-Veloxis Pharmaceuticals A/S, Endo Ventures enter deal to commercialize Envarsus XR in Canada

* Veloxis Pharmaceuticals A/S and Endo Ventures Limited jointly announce agreement for Paladin Labs Inc. To commercialize Envarsus XR® in Canada

BRIEF-Veloxis Pharmaceuticals signs deal with Chiesi Farmaceutici to commercialize Envarsus XR in China

* ANNOUNCES AGREEMENT WITH CHIESI FARMACEUTICI S.P.A. TO COMMERCIALIZE ENVARSUS XR IN CHINA

BRIEF-Veloxis and Endo Ventures announce agreement on commercialization in Canada

* VELOXIS PHARMACEUTICALS A/S AND ENDO VENTURES LIMITED JOINTLY ANNOUNCE AGREEMENT FOR PALADIN LABS INC. TO COMMERCIALIZE ENVARSUS XR® IN CANADA

BRIEF-Veloxis Pharmaceuticals Q1 operating loss narrows to $5.2 mln

* VELOXIS MAINTAINS ITS 2017 OUTLOOK OF OPERATING LOSS BEFORE THE RECOGNITION OF INCOME FROM LICENSE AGREEMENTS AND BEFORE ACCOUNTING FOR STOCK COMPENSATION TO BE IN THE RANGE OF USD 5 – 15 MILLION.

BRIEF-Veloxis increases share capital in connection with exercise of warrants

* CAPITAL INCREASED BY 1,000,000 NEW SHARES WITH A NOMINAL VALUE OF DKK 0.10 EACH CORRESPONDING TO NOMINALLY DKK 100,000 AS A CONSEQUENCE OF EXERCISE OF WARRANTS

Select another date: